vs
Side-by-side financial comparison of BV Financial, Inc. (BVFL) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $10.5M, roughly 1.2× BV Financial, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 45.6%, a 205.1% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 9.2%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 11.1%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
BVFL vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.5M | $12.6M |
| Net Profit | $4.8M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | 66.9% | — |
| Net Margin | 45.6% | 250.7% |
| Revenue YoY | 9.2% | 24080.8% |
| Net Profit YoY | 146.2% | 250.9% |
| EPS (diluted) | $0.52 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.5M | $12.6M | ||
| Q3 25 | $10.0M | $0 | ||
| Q2 25 | $9.9M | $0 | ||
| Q1 25 | $9.2M | $12.0K | ||
| Q4 24 | $9.7M | $52.0K | ||
| Q3 24 | $10.0M | $65.0K | ||
| Q2 24 | $9.5M | $114.0K | ||
| Q1 24 | $8.5M | $140.0K |
| Q4 25 | $4.8M | $31.5M | ||
| Q3 25 | $3.7M | $-7.4M | ||
| Q2 25 | $2.9M | $-1.7M | ||
| Q1 25 | $2.1M | $-13.9M | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $3.8M | $-17.1M | ||
| Q2 24 | $3.4M | $-17.9M | ||
| Q1 24 | $2.6M | $-12.7M |
| Q4 25 | 66.9% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 29.4% | -122758.3% | ||
| Q4 24 | 29.5% | — | ||
| Q3 24 | 52.4% | -28604.6% | ||
| Q2 24 | 49.6% | -16720.2% | ||
| Q1 24 | 42.1% | -9987.1% |
| Q4 25 | 45.6% | 250.7% | ||
| Q3 25 | 37.2% | — | ||
| Q2 25 | 29.0% | — | ||
| Q1 25 | 22.9% | -115550.0% | ||
| Q4 24 | 20.2% | — | ||
| Q3 24 | 38.0% | -26380.0% | ||
| Q2 24 | 35.8% | -15668.4% | ||
| Q1 24 | 30.1% | -9049.3% |
| Q4 25 | $0.52 | $0.56 | ||
| Q3 25 | $0.41 | $-0.13 | ||
| Q2 25 | $0.29 | $-0.03 | ||
| Q1 25 | $0.21 | $-0.25 | ||
| Q4 24 | $0.18 | — | ||
| Q3 24 | $0.35 | $-0.32 | ||
| Q2 24 | $0.32 | $-0.33 | ||
| Q1 24 | $0.24 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.7M | $40.3M |
| Total DebtLower is stronger | $35.0M | — |
| Stockholders' EquityBook value | $183.8M | $59.0M |
| Total Assets | $912.2M | $68.9M |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.7M | $40.3M | ||
| Q3 25 | $63.5M | $48.6M | ||
| Q2 25 | $56.3M | $31.2M | ||
| Q1 25 | $70.8M | $48.9M | ||
| Q4 24 | $70.5M | $52.9M | ||
| Q3 24 | $94.1M | $76.3M | ||
| Q2 24 | $90.6M | $63.5M | ||
| Q1 24 | $78.8M | $82.3M |
| Q4 25 | $35.0M | — | ||
| Q3 25 | $35.0M | — | ||
| Q2 25 | $35.0M | — | ||
| Q1 25 | $49.9M | — | ||
| Q4 24 | $49.9M | — | ||
| Q3 24 | $34.8M | — | ||
| Q2 24 | $34.8M | — | ||
| Q1 24 | $34.8M | — |
| Q4 25 | $183.8M | $59.0M | ||
| Q3 25 | $190.2M | $26.5M | ||
| Q2 25 | $198.0M | $32.8M | ||
| Q1 25 | $198.1M | $33.8M | ||
| Q4 24 | $195.5M | $46.1M | ||
| Q3 24 | $209.7M | $65.5M | ||
| Q2 24 | $205.5M | $80.5M | ||
| Q1 24 | $201.8M | $96.2M |
| Q4 25 | $912.2M | $68.9M | ||
| Q3 25 | $909.4M | $54.2M | ||
| Q2 25 | $908.3M | $62.1M | ||
| Q1 25 | $921.9M | $77.7M | ||
| Q4 24 | $911.8M | $110.5M | ||
| Q3 24 | $892.7M | $135.2M | ||
| Q2 24 | $897.2M | $149.9M | ||
| Q1 24 | $892.5M | $167.7M |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.17× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.0M | $-8.4M |
| Free Cash FlowOCF − Capex | $18.8M | — |
| FCF MarginFCF / Revenue | 178.2% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 3.96× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $34.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.0M | $-8.4M | ||
| Q3 25 | $8.4M | $17.4M | ||
| Q2 25 | $2.7M | $-17.7M | ||
| Q1 25 | $4.4M | $-4.0M | ||
| Q4 24 | $16.1M | $-23.4M | ||
| Q3 24 | $6.1M | $12.8M | ||
| Q2 24 | $1.5M | $-18.7M | ||
| Q1 24 | $4.6M | $5.9M |
| Q4 25 | $18.8M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $2.6M | — | ||
| Q1 25 | $4.2M | — | ||
| Q4 24 | $15.5M | — | ||
| Q3 24 | $6.0M | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $4.1M | — |
| Q4 25 | 178.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 46.0% | — | ||
| Q4 24 | 160.0% | — | ||
| Q3 24 | 59.6% | — | ||
| Q2 24 | 15.2% | — | ||
| Q1 24 | 48.4% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 3.96× | -0.26× | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | 8.23× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 1.77× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
